Prosecution Insights
Prosecution Insights
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONSHIPOURI, MARYAM | 1 | 79.0% | +37.3% |
| BOWERS, ERIN M | 1 | 55.1% | +10.5% |
| ALLEN, MARIANNE P | 1 | 60.2% | +18.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709913 | BOTULINUM NEUROTOXIN COMPOSITION | MONSHIPOURI, MARYAM | 15d overdue |
| 18023120 | ANTI-VEGF HEXAMERIC ANTIBODY AND COMPOSITION COMPRISING SAME | ALLEN, MARIANNE P | 76d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709913 | BOTULINUM NEUROTOXIN COMPOSITION | MONSHIPOURI, MARYAM | 15d overdue |
| 18023120 | ANTI-VEGF HEXAMERIC ANTIBODY AND COMPOSITION COMPRISING SAME | ALLEN, MARIANNE P | 76d |
| 18574838 | RECOMBINANT BOTULINUM TOXIN TYPE A LIGHT CHAIN, RECOMBINANT BOTULINUM TOXIN, AND COMPOSITION, USE, AND METHOD THEREOF | BOWERS, ERIN M | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1653 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709913 | BOTULINUM NEUROTOXIN COMPOSITION | MONSHIPOURI, MARYAM | 1651 | §102§103§112Other | Final Rejection | 15d overdue | Pending | May 14, 2024 |
| 18574838 | RECOMBINANT BOTULINUM TOXIN TYPE A LIGHT CHAIN, RECOMBINANT BOTULINUM TOXIN, AND COMPOSITION, USE, AND METHOD THEREOF | BOWERS, ERIN M | 1653 | §102 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18023120 | ANTI-VEGF HEXAMERIC ANTIBODY AND COMPOSITION COMPRISING SAME | ALLEN, MARIANNE P | 1647 | §102§103§112 | Final Rejection | 76d | Pending | Feb 24, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial